Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$87.00 USD

87.00
2,244

-0.28 (-0.32%)

Updated May 23, 2024 09:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Palatin Technologies (PTN) in Focus: Stock Moves 13.2% Higher

by Zacks Equity Research

Palatin Technologies (PTN) was a big mover last session, as the company saw its shares rise more than 13% on the day.

    Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher

    by Zacks Equity Research

    Catabasis Pharmaceuticals (CATB) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.

      MannKind (MNKD) in Focus: Stock Moves 7.8% Higher

      by Zacks Equity Research

      MannKind (MNKD) shares rose nearly 8% in the last trading session, amid huge volumes.

        Ligand's Captisol Deals Set to Drive Growth in the Long Run

        by Zacks Equity Research

        Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.

          Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day

          by Zacks Equity Research

          Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day

            David Bartosiak headshot

            Bull of the Day: Ligand Pharma (LGND)

            by David Bartosiak

            Drug stocks have become very hot lately and this off-the-radar name may soon be a big hit

              Ascendis Pharma (ASND) Looks Good: Stock Adds 5.5% in Session

              by Zacks Equity Research

              Ascendis Pharma (ASND) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

                Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher

                by Zacks Equity Research

                Aimmune Therapeutics (AIMT) shares rose more than 6% in the last trading session, amid huge volumes.

                  Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day

                  by Zacks Equity Research

                  Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day

                    Benjamin Rains headshot

                    3 Healthcare Stocks to Buy on Renewed Obamacare Repeal Talks

                    by Benjamin Rains

                    Healthcare has been a newsworthy topic for decades, and that is unlikely to cease anytime soon as the Republican effort to repeal and replace the Affordable Care Act, or Obamacare, ramps up ahead of a key Sept. 30 deadline.

                      Glaxo's Shingles Candidate Gets Positive FDA Committee Vote

                      by Zacks Equity Research

                      Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.

                        Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable

                        by Zacks Equity Research

                        Pfizer (PFE) announced final overall survival data from a phase III study (PROFILE 1014), evaluating its cancer drug Xalkori for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).

                          Arpita Dutt headshot

                          5 Top-Ranked Biotech Stocks to Buy Right Now

                          by Arpita Dutt

                          If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).

                            Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth

                            by Zacks Equity Research

                            Lilly (LLY) plans to reduce its global workforce by approximately 3,500 positions, which should save $500 million. Lilly plans to invest the savings in new drugs and overall growth of the company.

                              Alnylam Shares Plunge on Patient Death, Dosing Suspended

                              by Zacks Equity Research

                              Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.

                                Ligand (LGND) Up 9.6% Since Earnings Report: Can It Continue?

                                by Zacks Equity Research

                                Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Ligand (LGND) Diabetes Candidate Positive in Phase II Study

                                  by Zacks Equity Research

                                  Ligand's (LGND) diabetes candidate, LGD-6972, demonstrated a change of statistical significance in blood glucose level (HbA1c) from baseline over a treatment period of 12 weeks.

                                    Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6%

                                    by Zacks Equity Research

                                    Insmed Incorporated (INSM) was a big mover last session, as the company saw its shares rise nearly 120% on the day amid huge volumes.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data

                                      by Arpita Dutt

                                      Key highlights include pipeline updates from companies like Cellectis (CLLS) and Insmed. Insmed's shares skyrocketed on positive data from a late-stage study.

                                        Amgen Gets EU Nod to Expand Hyperparathyroidism Drug Label

                                        by Zacks Equity Research

                                        The European Commission approves Amgen's (AMGN) marketing application for Mimpara's pediatric formulation to heal secondary hyperparathyroidism (HPT).

                                          Top Ranked Momentum Stocks to Buy for August 30th

                                          by Zacks Equity Research

                                          Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 30th:

                                            3 Reasons Why Ligand Pharmaceuticals (LGND) is a Great Momentum Stock

                                            by Zacks Equity Research

                                            Momentum Stock Investors Will Love Ligand Pharmaceuticals (LGND) seeing its favorable price performance both in short and long term.

                                              Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S.

                                              by Zacks Equity Research

                                              Vertex Pharmaceuticals' (VRTX) regulatory applications for tezacaftor/ivacaftor (Kalydeco) combination have been accepted by the FDA and EMA for review.

                                                Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1%

                                                by Zacks Equity Research

                                                Myovant Sciences Ltd. (MYOV) was a big mover last session, as the company saw its shares rise over 16% on the day.

                                                  Can Ligand's Captisol Deals Boost Growth in the Long Run?

                                                  by Zacks Equity Research

                                                  Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, earning milestones and royalty payments from the same.